BRÈVE

sur Edesa Biotech (NASDAQ:EDSA)

Edesa Biotech to Participate in Upcoming Dermatology Meetings

Edesa Biotech, Inc., a biopharmaceutical company in the clinical-stage, has announced its plans to attend two significant dermatology events in March 2024. The company, known for its work on therapeutics for immuno-inflammatory diseases, aims to join the American Contact Dermatitis Society Annual Meeting on March 7, followed by the American Academy of Dermatology Annual Meeting from March 8-12, 2024, in San Diego, California. This participation reflects Edesa's commitment to advancing the conversation around treatments for dermatological conditions.

Interested attendees can arrange meetings with Edesa by reaching out via email. This initiative underlines the company’s aspirations to foster connections within the dermatology community. Edesa's portfolio includes promising treatments for various conditions, with projects ranging from a monoclonal antibody for Acute Respiratory Distress Syndrome in a Phase 3 study to a Phase 2 trial-approved treatment for vitiligo, and a topical treatment for Allergic Contact Dermatitis in development stages.

R. E.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Edesa Biotech